Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

S 26308

Known as: S-26308 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2002
Review
2002
  • M. Dahl
  • Journal of the American Academy of Dermatology
  • 2002
  • Corpus ID: 184867
T he articles in this supplement address the use of topically applied imiquimod (Aldara, R-837, S-26308) for the treatment of… Expand
Review
2001
Review
2001
  • S. Tyring
  • Skin therapy letter
  • 2001
  • Corpus ID: 42004647
Imiquimod (S-26308, R-837) (1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4 amine), and immune response modifier, was approved as… Expand
Highly Cited
1999
Highly Cited
1999
Imiquimod (also known as R-837 and S-26308) is an imidazoquinoline immune response modifier and is available in the US and… Expand
Review
1999
Review
1999
Imiquimod (S-26308, R-837) (1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4 amine), an immune response modifier, demonstrates… Expand
Highly Cited
1995
Highly Cited
1995
Imiquimod (R‐837, S‐26308) and the analogue S‐27609 were evaluated for cytokine induction in human blood cells. Both compounds… Expand